Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2026)
Vivos Therapeutics (VVOS) reported Share-based Compensation of $151000.0 for Q1 2026, down 52.37% year-over-year from $317000.0 in Q1 2025, and up 75.58% on a QoQ basis from $86000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Share-based Compensation data on file, last reported at $151000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 52.37% year-over-year to $151000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $637000.0 (down 91.42% YoY) and the FY2025 annual result came in at $700000.0, up 6263.64% from the prior year.
- Share-based Compensation climbed to $151000.0 in Q1 2026 per VVOS's latest filing, from $86000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $7.5 million in Q2 2024 and bottomed at -$689000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $300000.0 (2024), against an average of $699647.1.
- Peak annual rise in Share-based Compensation reached 1775.0% in 2024, while the deepest fall reached 571.92% in 2024.
- Tracing VVOS's Share-based Compensation over 5 years: stood at $775000.0 in 2022, then slumped by 81.16% to $146000.0 in 2023, then tumbled by 571.92% to -$689000.0 in 2024, then jumped by 112.48% to $86000.0 in 2025, then soared by 75.58% to $151000.0 in 2026.
- Per Business Quant, the three latest VVOS Share-based Compensation figures stand at $151000.0 (Q1 2026), $86000.0 (Q4 2025), and $100000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 87.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 94.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 43.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 12.90 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 151,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 151,000.00 |
| Mar 31, 2026 | 151,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 7.50 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 293,000.00 |
| Mar 31, 2024 | 293,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 400,000.00 |
| Mar 31, 2023 | 306,000.00 |
| Mar 31, 2023 | 306,000.00 |
| Dec 31, 2022 | 775,000.00 |
| Dec 31, 2022 | 775,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Mar 31, 2022 | 609,000.00 |
| Mar 31, 2022 | 609,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Sep 30, 2021 | 1.10 Mn |
| Sep 30, 2021 | 1.10 Mn |
| Jun 30, 2021 | 600,000.00 |
| Jun 30, 2021 | 600,000.00 |
| Mar 31, 2021 | 434,000.00 |
| Mar 31, 2021 | 434,000.00 |
| Dec 31, 2020 | 826,069.00 |
| Dec 31, 2020 | 826,069.00 |
| Sep 30, 2020 | 428,663.00 |
| Sep 30, 2020 | 428,663.00 |
| Jun 30, 2020 | 565,373.00 |
| Jun 30, 2020 | 565,373.00 |
| Mar 31, 2020 | 187,500.00 |
| Mar 31, 2020 | 187,500.00 |